Checa Alejandro, Castillo Alberto, Camacho Malena, Tapia William, Hernandez Isabel, Teran Enrique
Unidad de Atención Integral VIH/SIDA, Hospital Eugenio Espejo, Ministerio de Salud Publica del Ecuador, Quito, Ecuador.
Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Diego de Robles s/n y Pampite, Quito, Ecuador.
AIDS Res Ther. 2020 Jul 29;17(1):47. doi: 10.1186/s12981-020-00303-1.
It is well known that people living with HIV (PLWH) is in higher risk for the development of depression and it has also been suggested that the use of efavirenz into the antiretroviral regimens increases even that risk.
To evaluate the effect of efavirenz-containing antiretroviral regimens on the development of depression in newly ART initiated HIV patients in Ecuador.
In a prospective cohort study from June 2016 to May 2017, all newly HIV diagnosed patients at the HIV/AIDS Unit of the Hospital Eugenio Espejo in Quito, Ecuador were evaluated using the Hamilton Rating Scale for Depression followed by a second assessment 8-12 weeks after antiretroviral therapy containing efavirenz was initiated.
A total of 79 patients, mainly males younger than 35 years were studied. Majority of them were on TDF/FTC/EFV. Initial score in Hamilton Rating Scale revealed that less than 30% had no depression symptoms while almost 40% had mild depression. However, in the second assessment, 22.6% of the subjects had a score in the Hamilton Rating Scale compatible with severe or very severe depression (RR 1.58, 95% CI 1.09 to 2.28; p = 0.05).
In our cohort study, depression was much higher in patients on Efavirenz-containing treatments. Therefore, assessment for depression must be essential as part of follow-up in these patients.
众所周知，人类免疫缺陷病毒感染者（PLWH）患抑郁症的风险更高，也有人提出，在抗逆转录病毒治疗方案中使用依非韦伦会增加这种风险。
评估含依非韦伦的抗逆转录病毒治疗方案对厄瓜多尔新开始接受抗逆转录病毒治疗的HIV患者抑郁症发病情况的影响。
在2016年6月至2017年5月的一项前瞻性队列研究中，对厄瓜多尔基多市埃ugenio Espejo医院艾滋病科所有新诊断的HIV患者，使用汉密尔顿抑郁量表进行评估，在开始含依非韦伦的抗逆转录病毒治疗8 - 12周后进行第二次评估。
共研究了79例患者，主要是年龄小于35岁的男性。他们大多数接受替诺福韦/恩曲他滨/依非韦伦治疗。汉密尔顿抑郁量表初始评分显示，不到30%的患者没有抑郁症状，而近40%的患者有轻度抑郁。然而，在第二次评估中，22.6%的受试者汉密尔顿抑郁量表评分符合重度或极重度抑郁（相对危险度1.58，95%置信区间1.09至2.28；p = 0.05）。
在我们的队列研究中，接受含依非韦伦治疗的患者抑郁症发病率高得多。因此，对这些患者进行抑郁症评估作为随访的一部分至关重要。
